INVIVOGEN

Company Snapshot

Founded: 1997
Entity Type: Private
Region: U.S.
Headquarter: California, U.S.
Key Geographics: U.S.
Corporate Address: 10515 Vista Sorrento Pkwy, San Diego, California 92121 U.S. Tel. +1-888-457-5873 www.invivogen.com

Company Overview

InvivoGen was established in 1997 by scientists with technical expertise in microbiology. InvivoGen provides a wide range of biological molecules, including ultra-pure antibiotics, novel mycoplasma treatments, and an extensive collection of pattern-recognition receptor agonists derived from a wide range of microorganisms. The company also synthesizes molecules and plasmids for research use and conducts studies focused on gene therapy and vaccination, including coding sequences in expression plasmids for iPSC generation.

INVIVOGEN In Reports

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says global market for induced pluripotent stem cells is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028 at a CAGR of 9.1%.

Induced Pluripotent Stem Cells: Global Markets

BCC Research Market Report says induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate of 9.3%.

Induced Pluripotent Stem Cells: Global Markets

The global induced pluripotent stem cells (iPSC) market should reach $3.8 billion by 2024 from $2.4 billion in 2019 at a compound annual growth rate (CAGR) of 9.2% for the forecast period of 2019 to 2024. ...

Company's Business Segments

  • Products : Cell Culture, Cell Lines, PRR Ligands, Inhibitors, Antibodies and ELISAs, Vaccine Adjuvants, Proteins, Cloning and Expression, Genes and Promoters.
  • Services : PRR Ligand Screening, Custom Cloning.

Applications/End User Industries

  • Healthcare
AI Sentiment